Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease

MALVERN, Pa., March 20, 2018 -- (Healthcare Sales & Marketing Network) -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced ... Biopharmaceuticals, Ophthalmology Ocugen , OCU310, dry eye disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news